On January 30, 2020 AskAt Inc. (AskAt) reported that it received a Notice of Allowance dated January 21, 2020 from the United States Patent and Trademark Office (USPTO) in connection with Application No. 15/602,686, a use patent for AskAt’s EP4 antagonist AAT-007 in the treatment of epithelial cancers (Press release, AskAt, JAN 30, 2020, View Source [SID1234553677]). AskAt previously received an allowance for the use of AAT-007 in the treatment of gastric, lung, prostate, colon, and breast cancers. The current allowance significantly expands the use of AAT-007, covering most tumors that occur in a variety of tissues and organs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clinical Development of AskAt’s EP4 Antagonists for Cancer Immunotherapy
Ikena Oncology (formally Kyn Therapeutics, a parent company of Arrys Therapeutics, which licensed worldwide rights to AskAt’s EP4 antagonists except in China) and Ningbo NewBay Pharmaceutical Co. Ltd. (a subsidiary of Ningbo Tai Kang Medical Technology Co. Ltd., which licensed AskAt’s EP4 antagonists for cancer use in China), are currently conducting clinical studies of grapiprant (IK-007/RMX-1002) in the U.S. and China, respectively.